RhumbLine Advisers
URGN icon

RhumbLine Advisers’s UroGen Pharma URGN Stock Holding History

RhumbLine Advisers’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
54,922
+5,515
+11% +$149K ﹤0.01% 1928
2026
Q1 		$888K Buy
49,407
+3,647
+8% +$73.1K ﹤0.01% 2256
2025
Q4 		$1.07M Sell
45,760
-5,193
-10% -$113K ﹤0.01% 2186
2025
Q3 		$1.02M Sell
50,953
-340
-0.7% -$6.11K ﹤0.01% 2227
2025
Q2 		$703K Sell
51,293
-2,173
-4% -$20.9K ﹤0.01% 2441
2025
Q1 		$591K Buy
53,466
+2,196
+4% +$23.4K ﹤0.01% 2468
2024
Q4 		$546K Buy
51,270
+1,402
+3% +$16.8K ﹤0.01% 2627
2024
Q3 		$633K Sell
49,868
-609
-1% -$9.04K ﹤0.01% 2545
2024
Q2 		$847K Buy
50,477
+13,681
+37% +$195K ﹤0.01% 2329
2024
Q1 		$552K Buy
36,796
+2,090
+6% +$34.2K ﹤0.01% 2614
2023
Q4 		$521K Buy
34,706
+7,842
+29% +$102K ﹤0.01% 2636
2023
Q3 		$376K Buy
26,864
+6,458
+32% +$104K ﹤0.01% 2792
2023
Q2 		$211K Buy
+20,406
New +$225K ﹤0.01% 3215
2022
Q2 		– Sell
-23,152
Closed -$202K – 3240
2022
Q1 		$202K Sell
23,152
-912
-4% -$7.11K ﹤0.01% 2757
2021
Q4 		$229K Sell
24,064
-344
-1% -$4.85K ﹤0.01% 2797
2021
Q3 		$411K Buy
24,408
+505
+2% +$8.01K ﹤0.01% 2631
2021
Q2 		$365K Sell
23,903
-2,675
-10% -$48.4K ﹤0.01% 2711
2021
Q1 		$518K Sell
26,578
-2,070
-7% -$43.9K ﹤0.01% 2477
2020
Q4 		$516K Buy
28,648
+3,131
+12% +$65.6K ﹤0.01% 2434
2020
Q3 		$492K Sell
25,517
-3,570
-12% -$80.8K ﹤0.01% 2299
2020
Q2 		$760K Buy
29,087
+5,539
+24% +$135K ﹤0.01% 2167
2020
Q1 		$420K Buy
23,548
+143
+0.6% +$3.86K ﹤0.01% 2249
2019
Q4 		$781K Buy
23,405
+1,395
+6% +$38.1K ﹤0.01% 2191
2019
Q3 		$524K Buy
22,010
+931
+4% +$30.4K ﹤0.01% 2302
2019
Q2 		$758K Buy
+21,079
New +$777K ﹤0.01% 2181

Other funds holding URGN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
JFG
Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

RhumbLine Advisers's URGN Position: Q2 2026 in Review

RhumbLine Advisers increased its UroGen Pharma (URGN) stake by 11% in Q2 2026, buying an estimated $149K and bringing the position to 54,922 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1928.

RhumbLine Advisers first reported a position in URGN in Q2 2019 and has held it in 25 quarters since. 190 funds tracked by Wall St. Rank hold URGN as of Q2 2026.

  • RhumbLine Advisers held 54,922 shares of UroGen Pharma worth $2.02M as of Q2 2026.
  • RhumbLine Advisers bought 5,515 UroGen Pharma shares in Q2 2026, an estimated $149K.
  • UroGen Pharma made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1928 holding.
  • RhumbLine Advisers first reported a position in UroGen Pharma in Q2 2019 and has held it in 25 quarters since.
  • 190 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.